Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
27.06
-1.30 (-4.57%)
Aug 5, 2026, 1:18 PM EDT - Market open
Beam Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 219.83 | 294.94 | 281.97 | 435.9 | 232.77 | 559.99 |
Short-Term Investments | 933.1 | 950.27 | 568.77 | 753.98 | 845.37 | 405.65 |
Cash & Short-Term Investments | 1,153 | 1,245 | 850.74 | 1,190 | 1,078 | 965.65 |
Cash Growth | 0.22% | 46.37% | -28.50% | 10.36% | 11.65% | 222.24% |
Other Receivables | - | - | - | - | - | 300 |
Total Trade Receivables | - | - | - | - | - | 300 |
Other Current Assets | 25.67 | 23.48 | 27.41 | 21.17 | 14.76 | 7.36 |
Total Current Assets | 1,179 | 1,269 | 878.15 | 1,211 | 1,093 | 1,273 |
Net Property, Plant & Equipment | 193.19 | 205.18 | 216.28 | 237.81 | 234.13 | 186.98 |
Other Long-Term Assets | 14.57 | 7.31 | 9.4 | 10.87 | 14.69 | 14.47 |
Total Assets | 1,386 | 1,481 | 1,104 | 1,460 | 1,342 | 1,474 |
Accounts Payable | 13.1 | 10.23 | 3.87 | 1.62 | 9.03 | 7.47 |
Accrued Expenses | 40.41 | 55.27 | 47.47 | 111.66 | 49.91 | 67.66 |
Current Portion of Long-Term Debt | - | - | - | - | - | 2.29 |
Current Portion of Leases | 15.21 | 14.36 | 13.47 | 12.78 | 10.38 | 7.54 |
Unearned Revenue | - | 6.66 | 108.86 | 68.71 | 135.97 | 86.27 |
Other Current Liabilities | 12.17 | 10.41 | 8.4 | 10.8 | 18.3 | 42.2 |
Total Current Liabilities | 80.88 | 96.94 | 182.07 | 205.57 | 223.6 | 213.44 |
Long-Term Debt | 100.26 | - | - | - | - | 3.01 |
Long-Term Leases | 131.89 | 139.76 | 147.96 | 159.91 | 168.63 | 134.81 |
Other Long-Term Liabilities | 5.88 | 6.13 | 40.26 | 112.91 | 216.02 | 296.46 |
Total Long-Term Liabilities | 238.03 | 145.88 | 188.21 | 272.82 | 384.65 | 434.28 |
Total Liabilities | 318.91 | 242.82 | 370.28 | 478.39 | 608.24 | 647.72 |
Common Stock | 1.03 | 1.02 | 0.84 | 0.82 | 0.71 | 0.68 |
Additional Paid-in Capital | 2,927 | 2,877 | 2,299 | 2,170 | 1,793 | 1,594 |
Accumulated Other Comprehensive Income | -2.19 | 1.11 | 0.68 | 0.6 | -2.43 | -0.05 |
Retained Earnings | -1,858 | -1,641 | -1,567 | -1,190 | -1,057 | -768.27 |
Shareholders' Equity | 1,067 | 1,238 | 733.55 | 981.33 | 733.47 | 826.74 |
Total Liabilities & Equity | 1,386 | 1,481 | 1,104 | 1,460 | 1,342 | 1,474 |
Total Debt | 247.36 | 154.12 | 161.43 | 172.69 | 179.01 | 147.64 |
Net Cash (Debt) | 905.57 | 1,091 | 689.32 | 1,017 | 899.13 | 818 |
Net Cash Growth | -9.04% | 58.29% | -32.23% | 13.13% | 9.92% | 325.98% |
Net Cash Per Share | 8.73 | 11.03 | 8.37 | 13.18 | 12.84 | 12.74 |
Book Value | 1,067 | 1,238 | 733.55 | 981.33 | 733.47 | 826.74 |
Book Value Per Share | 10.29 | 12.52 | 8.91 | 12.72 | 10.48 | 12.87 |
Tangible Book Value | 1,067 | 1,238 | 733.55 | 981.33 | 733.47 | 826.74 |
Tangible Book Value Per Share | 10.29 | 12.52 | 8.91 | 12.72 | 10.48 | 12.87 |